Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old

Robert B. Belshe, Frances K. Newman, Theodore F. Tsai, Ruth A Karron, Keith Reisinger, Don Roberton, Helen Marshall, Richard Schwartz, James King, Frederick W. Henderson, William Rodriguez, Joseph M. Severs, Peter F. Wright, Harry Keyserling, Geoffrey A. Weinberg, Kenneth Bromberg, Richard Loh, Peter Sly, Peter McIntyre, John B. Ziegler & 8 others Jill Hackell, Anne Deatly, Alice Georgiu, Maribel Paschalis, Shin Lu Wu, Joanne M. Tatem, Brian Murphy, Edwin Anderson

Research output: Contribution to journalArticle

Abstract

A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6-18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature ≥38°C) was noted during the 14 days after vaccination. There was no difference between groups in the occurrence of acute otitis media or serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a ≥4-fold increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group and

Original languageEnglish (US)
Pages (from-to)462-470
Number of pages9
JournalJournal of Infectious Diseases
Volume189
Issue number3
DOIs
StatePublished - Feb 1 2004

Fingerprint

Paramyxoviridae Infections
Attenuated Vaccines
Vaccines
Vaccination
Placebos
Otitis Media with Effusion
Antibodies
Otitis Media
Nose
Cough
Temperature
Serum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old. / Belshe, Robert B.; Newman, Frances K.; Tsai, Theodore F.; Karron, Ruth A; Reisinger, Keith; Roberton, Don; Marshall, Helen; Schwartz, Richard; King, James; Henderson, Frederick W.; Rodriguez, William; Severs, Joseph M.; Wright, Peter F.; Keyserling, Harry; Weinberg, Geoffrey A.; Bromberg, Kenneth; Loh, Richard; Sly, Peter; McIntyre, Peter; Ziegler, John B.; Hackell, Jill; Deatly, Anne; Georgiu, Alice; Paschalis, Maribel; Wu, Shin Lu; Tatem, Joanne M.; Murphy, Brian; Anderson, Edwin.

In: Journal of Infectious Diseases, Vol. 189, No. 3, 01.02.2004, p. 462-470.

Research output: Contribution to journalArticle

Belshe, RB, Newman, FK, Tsai, TF, Karron, RA, Reisinger, K, Roberton, D, Marshall, H, Schwartz, R, King, J, Henderson, FW, Rodriguez, W, Severs, JM, Wright, PF, Keyserling, H, Weinberg, GA, Bromberg, K, Loh, R, Sly, P, McIntyre, P, Ziegler, JB, Hackell, J, Deatly, A, Georgiu, A, Paschalis, M, Wu, SL, Tatem, JM, Murphy, B & Anderson, E 2004, 'Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old', Journal of Infectious Diseases, vol. 189, no. 3, pp. 462-470. https://doi.org/10.1086/381184
Belshe, Robert B. ; Newman, Frances K. ; Tsai, Theodore F. ; Karron, Ruth A ; Reisinger, Keith ; Roberton, Don ; Marshall, Helen ; Schwartz, Richard ; King, James ; Henderson, Frederick W. ; Rodriguez, William ; Severs, Joseph M. ; Wright, Peter F. ; Keyserling, Harry ; Weinberg, Geoffrey A. ; Bromberg, Kenneth ; Loh, Richard ; Sly, Peter ; McIntyre, Peter ; Ziegler, John B. ; Hackell, Jill ; Deatly, Anne ; Georgiu, Alice ; Paschalis, Maribel ; Wu, Shin Lu ; Tatem, Joanne M. ; Murphy, Brian ; Anderson, Edwin. / Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 3. pp. 462-470.
@article{a4d731c749094f179c214b8242269779,
title = "Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old",
abstract = "A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6-18 months old; 226 children (59{\%}) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature ≥38°C) was noted during the 14 days after vaccination. There was no difference between groups in the occurrence of acute otitis media or serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84{\%} of seronegative vaccine recipients developed a ≥4-fold increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group and",
author = "Belshe, {Robert B.} and Newman, {Frances K.} and Tsai, {Theodore F.} and Karron, {Ruth A} and Keith Reisinger and Don Roberton and Helen Marshall and Richard Schwartz and James King and Henderson, {Frederick W.} and William Rodriguez and Severs, {Joseph M.} and Wright, {Peter F.} and Harry Keyserling and Weinberg, {Geoffrey A.} and Kenneth Bromberg and Richard Loh and Peter Sly and Peter McIntyre and Ziegler, {John B.} and Jill Hackell and Anne Deatly and Alice Georgiu and Maribel Paschalis and Wu, {Shin Lu} and Tatem, {Joanne M.} and Brian Murphy and Edwin Anderson",
year = "2004",
month = "2",
day = "1",
doi = "10.1086/381184",
language = "English (US)",
volume = "189",
pages = "462--470",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6-18 Months Old

AU - Belshe, Robert B.

AU - Newman, Frances K.

AU - Tsai, Theodore F.

AU - Karron, Ruth A

AU - Reisinger, Keith

AU - Roberton, Don

AU - Marshall, Helen

AU - Schwartz, Richard

AU - King, James

AU - Henderson, Frederick W.

AU - Rodriguez, William

AU - Severs, Joseph M.

AU - Wright, Peter F.

AU - Keyserling, Harry

AU - Weinberg, Geoffrey A.

AU - Bromberg, Kenneth

AU - Loh, Richard

AU - Sly, Peter

AU - McIntyre, Peter

AU - Ziegler, John B.

AU - Hackell, Jill

AU - Deatly, Anne

AU - Georgiu, Alice

AU - Paschalis, Maribel

AU - Wu, Shin Lu

AU - Tatem, Joanne M.

AU - Murphy, Brian

AU - Anderson, Edwin

PY - 2004/2/1

Y1 - 2004/2/1

N2 - A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6-18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature ≥38°C) was noted during the 14 days after vaccination. There was no difference between groups in the occurrence of acute otitis media or serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a ≥4-fold increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group and

AB - A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6-18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature ≥38°C) was noted during the 14 days after vaccination. There was no difference between groups in the occurrence of acute otitis media or serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a ≥4-fold increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group and

UR - http://www.scopus.com/inward/record.url?scp=10744229464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229464&partnerID=8YFLogxK

U2 - 10.1086/381184

DO - 10.1086/381184

M3 - Article

VL - 189

SP - 462

EP - 470

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -